FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2804591625> ?p ?o ?g. }

• W2804591625 endingPage "e180171" @default.
• W2804591625 startingPage "e180171" @default.
• W2804591625 abstract "<h3>Importance</h3> Antithrombotic therapies are effective in both primary and secondary stroke prophylaxis in high-risk patients with atrial fibrillation (AF), but they are often underused in community practice. <h3>Objective</h3> To examine prestroke and poststroke antithrombotic treatment patterns and long-term outcomes in patients with AF presenting with ischemic stroke. <h3>Design, Setting, and Participants</h3> A retrospective cohort study of Danish patients with AF, with a prestroke CHA₂DS₂-VASc score of 1 or higher for men and 2 or higher for women, and presenting with ischemic stroke was conducted from January 1, 2004, to January 31, 2017. Data on hospital admission, prescription fillings, and vital status were assessed using several Danish nationwide registries. <h3>Exposures</h3> Patients who survived 100 days after discharge were divided into 3 groups according to poststroke antithrombotic therapy: oral anticoagulation (OAC) therapy, antiplatelet therapy alone, or no antithrombotic therapy. <h3>Main Outcomes and Measures</h3> Long-term outcomes (thromboembolic events and bleeding complications) were examined using multivariable Cox regression analyses across the 3 groups. <h3>Results</h3> Among 30 626 patients with AF admitted with ischemic stroke, 11 139 patients (36.3%) received OAC therapy (44.3% female; median age, 79 years [interquartile range, 73-85 years]), 11 874 (38.8%) received antiplatelet therapy alone (55.0% female; median age, 82 years [interquartile range, 75-88 years]), and 7613 (24.9%) received no antithrombotic therapy before stroke (53.8% female; median age, 80 years [interquartile range, 71-86 years]). Following stroke, 31.3% of those receiving antiplatelet therapy alone and 43.7% of those receiving no antithrombotic therapy before stroke shifted to OAC therapy. Yet, 37.5% of patients with stroke did not receive OAC therapy following stroke. However, OAC treatment rates increased over time. During a maximum of 10 years of follow-up, 17.5%, 21.2%, and 21.5% experienced a new thromboembolic event and 72.7%, 86.4%, and 86.2% died among those treated with OAC therapy, antiplatelet therapy, or no antithrombotic therapy, respectively. Poststroke OAC therapy was associated with lower risk of recurrent thromboembolic events (adjusted hazard ratio, 0.81; 95% CI, 0.73-0.89) and no significant difference in bleeding complications (adjusted hazard ratio, 0.97; 95% CI, 0.86-1.10), compared with no poststroke antithrombotic therapy. In contrast, there were no significant differences for those treated with poststroke antiplatelet therapy and no antithrombotic therapy. <h3>Conclusions and Relevance</h3> Patients with AF receiving poststroke OAC therapy had lower risk of recurrent thromboembolic events. Our findings suggest a substantial opportunity for improving primary and secondary stroke prophylaxis in high-risk patients with AF." @default.
• W2804591625 created "2018-06-01" @default.
• W2804591625 creator A5024446704 @default.
• W2804591625 creator A5033436516 @default.
• W2804591625 creator A5035803645 @default.
• W2804591625 creator A5039739369 @default.
• W2804591625 creator A5041526130 @default.
• W2804591625 creator A5045179017 @default.
• W2804591625 creator A5070062505 @default.
• W2804591625 creator A5081057548 @default.
• W2804591625 creator A5087403596 @default.
• W2804591625 creator A5087431344 @default.
• W2804591625 date "2018-05-18" @default.
• W2804591625 modified "2023-10-14" @default.
• W2804591625 title "Prestroke and Poststroke Antithrombotic Therapy in Patients With Atrial Fibrillation" @default.
• W2804591625 cites W1480729244 @default.
• W2804591625 cites W1893217911 @default.
• W2804591625 cites W1919258584 @default.
• W2804591625 cites W1974375858 @default.
• W2804591625 cites W1996801902 @default.
• W2804591625 cites W1999468381 @default.
• W2804591625 cites W2004592440 @default.
• W2804591625 cites W2011030196 @default.
• W2804591625 cites W2022095549 @default.
• W2804591625 cites W2023143117 @default.
• W2804591625 cites W2028298306 @default.
• W2804591625 cites W2040452288 @default.
• W2804591625 cites W2056314295 @default.
• W2804591625 cites W2060284271 @default.
• W2804591625 cites W2067443499 @default.
• W2804591625 cites W2094757280 @default.
• W2804591625 cites W2095591963 @default.
• W2804591625 cites W2096246254 @default.
• W2804591625 cites W2097854437 @default.
• W2804591625 cites W2099442549 @default.
• W2804591625 cites W2102420102 @default.
• W2804591625 cites W2102924526 @default.
• W2804591625 cites W2104343448 @default.
• W2804591625 cites W2114635452 @default.
• W2804591625 cites W2124247204 @default.
• W2804591625 cites W2135644575 @default.
• W2804591625 cites W2136489990 @default.
• W2804591625 cites W2142749836 @default.
• W2804591625 cites W2143681591 @default.
• W2804591625 cites W2144582288 @default.
• W2804591625 cites W2147108549 @default.
• W2804591625 cites W2152623033 @default.
• W2804591625 cites W2157711058 @default.
• W2804591625 cites W2162508946 @default.
• W2804591625 cites W2164861810 @default.
• W2804591625 cites W2298220628 @default.
• W2804591625 cites W2435343268 @default.
• W2804591625 cites W2465663631 @default.
• W2804591625 cites W2475249835 @default.
• W2804591625 cites W2509795914 @default.
• W2804591625 cites W2518330835 @default.
• W2804591625 cites W2579323441 @default.
• W2804591625 cites W2603057432 @default.
• W2804591625 cites W2612450531 @default.
• W2804591625 cites W2617778826 @default.
• W2804591625 cites W3004050106 @default.
• W2804591625 cites W4285719527 @default.
• W2804591625 cites W4292550095 @default.
• W2804591625 cites W4362054082 @default.
• W2804591625 doi "https://doi.org/10.1001/jamanetworkopen.2018.0171" @default.
• W2804591625 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6324317" @default.
• W2804591625 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30646049" @default.
• W2804591625 hasPublicationYear "2018" @default.
• W2804591625 type Work @default.
• W2804591625 sameAs 2804591625 @default.
• W2804591625 citedByCount "24" @default.
• W2804591625 countsByYear W28045916252018 @default.
• W2804591625 countsByYear W28045916252019 @default.
• W2804591625 countsByYear W28045916252020 @default.
• W2804591625 countsByYear W28045916252021 @default.
• W2804591625 countsByYear W28045916252022 @default.
• W2804591625 countsByYear W28045916252023 @default.
• W2804591625 crossrefType "journal-article" @default.
• W2804591625 hasAuthorship W2804591625A5024446704 @default.
• W2804591625 hasAuthorship W2804591625A5033436516 @default.
• W2804591625 hasAuthorship W2804591625A5035803645 @default.
• W2804591625 hasAuthorship W2804591625A5039739369 @default.
• W2804591625 hasAuthorship W2804591625A5041526130 @default.
• W2804591625 hasAuthorship W2804591625A5045179017 @default.
• W2804591625 hasAuthorship W2804591625A5070062505 @default.
• W2804591625 hasAuthorship W2804591625A5081057548 @default.
• W2804591625 hasAuthorship W2804591625A5087403596 @default.
• W2804591625 hasAuthorship W2804591625A5087431344 @default.
• W2804591625 hasBestOaLocation W28045916251 @default.
• W2804591625 hasConcept C119060515 @default.
• W2804591625 hasConcept C126322002 @default.
• W2804591625 hasConcept C127413603 @default.
• W2804591625 hasConcept C164705383 @default.
• W2804591625 hasConcept C167135981 @default.
• W2804591625 hasConcept C1862650 @default.
• W2804591625 hasConcept C187212893 @default.
• W2804591625 hasConcept C201903717 @default.
• W2804591625 hasConcept C2426938 @default.

• next